Market Newsdesk

Ended 2024 with $71.1 million of cash and cash equivalents and no debt

Conference Call and Webcast Scheduled for Tuesday, March 25, 2025, at 8:30 a.m. Eastern Time

SEATTLE, March 25, 2025 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced its financial results for the full year ended December 31, 2024 and provided an update on recent company developments.

Fourth Quarter and Early 2025 Highlights

• Strategic Decision to Pursue Metastatic Breast Cancer Indication: Atossa plans to advance its lead program, (Z)-endoxifen, to target metastatic breast cancer. The Company believes this approach may offer a more streamlined regulatory pathway to deliver (Z)-endoxifen to patients with urgent unmet medical needs, as the current treatment options for metastatic breast cancer often provides limited durability of response and substantial side effects. (Z)-endoxifen—a potent and well-tolerated selective estrogen receptor modulator (SERM)—has shown encouraging signs in previous clinical trials, which Atossa believes supports its potential to fill this critical gap in treatment. Atossa also intends to continue engagement with the U.S. Food and Drug Administration (FDA) to advance additional indications, including breast cancer prevention and neoadjuvant therapy, which typically require larger and longer clinical trials.
• Tolerability and Pharmacokinetic Data from Phase 2 Evangeline Trial: Atossa presented three posters at the San Antonio Breast Cancer Symposium (SABCS) highlighting pharmacokinetic (PK) and tolerability data from the Phase 2 EVANGELINE trial. This randomized, non-inferiority study evaluates (Z)-endoxifen in premenopausal women with primary ER+/HER2- breast cancer as a neoadjuvant treatment. Substantial tumor suppression was observed across all dosing levels, with or without ovarian function suppression (OFS or goserelin). The 4-week Ki-67 ≤ 10 percent response rate was generally above 85 percent across dose levels, with or without the presence of OFS. Overall, (Z)-endoxifen was well tolerated and target tissue steady state concentration (Css) levels were achieved without significant Grade 3 or 4 toxicities. Given the gynecologic events that were previously reported in the 80 mg groups, the study is expected to continue under an amended protocol as a randomized trial that compares (Z)-endoxifen 40 mg per day with OFS to exemestane plus OFS, using the 4-week Ki-67 reduction as the primary endpoint. Additionally, the trial is expected to include a single arm cohort with a 40 mg (Z)-endoxifen monotherapy neoadjuvant treatment, using a 24-week Ki-67 endpoint.
• Full Results from Phase 2 KARISMA-Endoxifen Study: Additional SABCS data showcased the potential of low-dose (Z)-endoxifen to significantly reduce mammographic breast density (MBD). In the trial, a 1 mg dose reduced MBD by 17.3 percentage points (p<0.01), while a 2 mg dose achieved a 23.5 percentage-point reduction (p<0.01), compared to just 0.27 percentage points in the placebo arm, which we believe highlights the effectiveness of the lower dose in achieving significant reductions. Importantly, no significant differences in adverse events of special interest were observed between the 1 mg dose and the placebo. The 2 mg dose was associated with higher rates of hot flashes, night sweats and vaginal discharge compared to the placebo group. We believe these findings further support the therapy’s favorable safety and efficacy profile.

“Metastatic breast cancer remains an area of critical unmet need, where improved therapies are urgently required,” said Steven Quay, M.D., Ph.D., President and Chief Executive Officer of Atossa. “(Z)-endoxifen has demonstrated promising anti-estrogenic and anti-tumor effects alongside a favorable tolerability profile, which we believe positions it as a potential next-generation therapy. We believe that pursuing an initial approval in metastatic breast cancer could offer a more efficient regulatory pathway, potentially enabling us to make (Z)-endoxifen available sooner to the patients who need it most. We also believe this strategy further supports our ability to expand the broader potential of (Z)-endoxifen to address multiple stages of breast cancer, from reducing tumor growth to preventing recurrence after successful treatment.”

Conference Call Information:

The webcast will be available at the investor relations section of the Company’s website at atossatherapeutics.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “Atossa Therapeutics Business Update” to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s website at atossatherapeutics.com.

Comparison of Years Ended December 31, 2024 and 2023

Operating Expenses
. Total operating expenses were $27.6 million for the year ended December 31, 2024, which was a decrease of $3.8 million, from the year ended December 31, 2023 of $31.4 million. Factors contributing to the decreased operating expenses in the year ended December 31, 2024 are explained below.

Research & Development (R&D) Expenses
. The following table provides a breakdown of major categories within R&D expenses for the years ended December 31, 2024 and 2023, together with the dollar change in those categories (dollars in thousands):

			Year Ended December 31, 2024				Year Ended December 31, 2023				Increase (Decrease)				% Increase (Decrease)
Research and Development Expense
	Clinical and pre-clinical trials		$	10,107			$	12,722			$	(2,615	)		(21	)%
	Compensation			2,928				3,474				(546	)		(16	)%
	Professional fees and other			1,082				1,138				(56	)		(5	)%
	Research and Development Expense Total		$	14,117			$	17,334			$	(3,217	)		(19	)%

•	Clinical and pre-clinical trial expense decreased $2.6 million for the year ended December 31, 2024 compared to the prior year due to a decrease in spending for the (Z)-endoxifen trials, including a decrease in drug development costs.
•	The decrease in R&D compensation expense of $0.5 million for the year ended December 31, 2024 compared to the prior year was primarily due to a decrease in non-cash stock-based compensation expense of $0.9 million. Non-cash stock-based compensation expense decreased compared to the prior year due to the weighted average fair value of stock options amortizing in 2024 being lower than 2023. The decrease in compensation expense was partially offset by an increase in cash compensation expense of $0.4 million due to the hiring in early 2024 of additional R&D employees.

 

  
General and Administrative (G&A) Expenses. The following table provides a breakdown of major categories within G&A expenses for the years ended December 31, 2024 and 2023, together with the dollar change in those categories (dollars in thousands):

			Year Ended December 31, 2024				Year Ended December 31, 2023				Increase (Decrease)				% Increase (Decrease)
General and Administrative Expense
	Compensation		$	5,458			$	7,388			$	(1,930	)		(26	)%
	Professional fees and other			7,164				5,367				1,797			33	%
	Insurance			882				1,288				(406	)		(32	)%
	General and Administrative Expense Total		$	13,504			$	14,043			$	(539	)		(4	)%

•	The decrease in G&A compensation expense of $1.9 million for the year ended December 31, 2024 compared to the prior year was due to a decrease in both cash compensation and non-cash stock-based compensation expense. Non-cash stock-based compensation expense decreased by $1.4 million for the year ended December 31, 2024 compared to the prior year due to the weighted average fair value of stock options amortizing in 2024 being lower than in 2023. Cash compensation decreased by $0.5 million for the year ended December 31, 2024 compared to the prior year primarily due to salary and bonus severance expense of $0.6 million related to the departure of our former Chief Financial Officer in 2023.
•	G&A professional fees and other expense increased by $1.8 million for the year ended December 31, 2024 compared to the prior year primarily due to the increase in legal fees of $1.1 million for the year ended December 31, 2024. Legal costs for the PGR litigation and patent defense in 2024 increased $0.7 million, and we also incurred legal costs associated with the filing of our Registration Statement on Form S-3 and the establishment of our ATM facility of $0.4 million. Investor relations expense increased by $0.3 million for the year ended December 31, 2024 compared to the prior year due to an increase in investor outreach costs. Accounting fees also increased by $0.3 million for the year ended December 31, 2024 compared to the prior year due to procedures needed from both current and former auditors related to the Registration Statement on Form S-3 and our ATM facility.
•	The decrease in G&A insurance expense of $0.4 million for the year ended December 31, 2024 compared to the prior year was due to lower negotiated insurance premiums for the same or better coverage in 2024.

Interest Income. Interest income of $4.1 million for the year ended December 31, 2024 represented a decrease of $0.2 million compared to the prior year and was primarily due to a decrease in funds invested in the money market account.

Impairment Charge on Investment in Equity Securities. For the years ended December 31, 2024 and 2023, we wrote down our investment in equity securities by $1.7 million and $3.0 million, respectively, due to impairment of our investment in Dynamic Cell Therapies, Inc.

About (Z)-Endoxifen

(Z)-endoxifen is one of the most potent Selective Estrogen Receptor Modulator (SERM) for estrogen receptor inhibition and may cause estrogen receptor degradation. It has also been shown to have efficacy in the setting of patients with tumor resistance to other hormonal treatments. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCβ1, a known oncogenic protein, at clinically attainable blood concentrations. Finally, (Z)-endoxifen appears to deliver similar or even greater bone agonistic effects while resulting in little or no endometrial proliferative effects compared with standard treatments, like tamoxifen.

Atossa is developing a proprietary oral formulation of (Z)-endoxifen that is encapsulated to bypass the stomach, as acidic conditions in the stomach convert a significant proportion of (Z)-endoxifen to the inactive (E)-endoxifen. Atossa’s (Z)-endoxifen has been shown to be well tolerated in clinical studies of women with and without breast cancer. (Z)-endoxifen is currently being studied in four Phase 2 trials: one in women diagnosed with ductal carcinoma in situ, and three other studies including the EVANGELINE study and two I-SPY studies in women with ER+/HER2- breast cancer. Atossa’s (Z)-endoxifen is protected by three issued U.S. patents and numerous pending patent applications.

About Atossa Therapeutics

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions. The company’s lead product candidate, (Z)-endoxifen, is a highly potent SERM designed for use across the breast cancer spectrum, including prevention, neoadjuvant, adjuvant, and metastatic settings. Atossa is committed to advancing its robust clinical research programs to improve patient outcomes while creating sustainable value for shareholders. For more information, visit atossatherapeutics.com.

FORWARD LOOKING STATEMENTS

This press release contains certain information that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may identify these forward-looking statements by the use of words such as “expect,” “potential,” “continue,” “may,” “will,” “should,” “could,” “would,” “seek,” “intend,” “plan,” “estimate,” “anticipate,” “believe,” “design,” “predict,” “future,” or other comparable words. All statements made in this press release that are not statements of historical fact, including statements regarding data related to the (Z)-endoxifen program, the safety, tolerability and efficacy of (Z)-endoxifen, the potential of (Z)-endoxifen as a breast cancer prevention and treatment agent, the potential indications that the Company may pursue for (Z)-endoxifen, the potential for (Z)-endoxifen to receive regulatory approval, benefits of the Company’s strategy of pursuing a metastatic indication for (Z)-endoxifen, the expected design and enrollment of trials and timing of data and related publications, and the potential market and growth opportunities for the Company, are forward-looking statements. Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results, outcomes, or the timing of actual results or outcomes, to differ materially from those projected or anticipated, including risks and uncertainties associated with: our ability to obtain patent coverage for our product candidates; macroeconomic conditions and increasing geopolitical instability; the expected timing of releasing data; any variation between interim or preliminary and final clinical results or analysis; actions and inactions by the FDA and foreign regulatory bodies; the outcome or timing of regulatory approvals needed by Atossa, including those needed to continue our planned (Z)-endoxifen trials; our ability to satisfy regulatory requirements; our ability to regain compliance or maintain compliance with the continued listing requirements of the Nasdaq Stock Market; our ability to successfully develop and commercialize new therapeutics; the success, costs and timing of our development activities, including our ability to successfully initiate or complete our clinical trials, including our (Z)-endoxifen trials; our anticipated rate of patient enrollment; our ability to contract with third-parties and their ability to perform adequately; our estimates on the size and characteristics of our potential markets; our ability to successfully defend litigation and other similar complaints and to establish and maintain intellectual property rights covering our products; whether we can successfully complete our clinical trial of oral (Z)-endoxifen in women with mammographic breast density and our trials of (Z)-endoxifen in women with breast cancer, and whether the studies will meet their objectives; our expectations as to future financial performance, expense levels and capital sources, including our ability to raise capital; our ability to attract and retain key personnel; our anticipated working capital needs and expectations around the sufficiency of our cash reserves; and other risks and uncertainties detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its Annual Reports on Form 10-K and Quarterly Reports on 10-Q. Forward-looking statements are presented as of the date of this press release. Except as required by law, we do not intend to update any forward-looking statements, whether as a result of new information, future events or circumstances or otherwise.

Contact:

Michael Parks
VP, Investor and Public Relations
484-356-7105
[email protected]

ATOSSA THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except share and per share data)
		As of December 31,
		2024				2023
Assets
Current assets
Cash and cash equivalents		$	71,084			$	88,460
Restricted cash			110				110
Prepaid materials			2,098				1,487
Prepaid expenses and other current assets			1,165				2,162
Total current assets			74,457				92,219
Investment in equity securities			—				1,710
Other assets			1,987				2,323
Total assets		$	76,444			$	96,252
Liabilities and stockholders’ equity
Current liabilities
Accounts payable		$	679			$	806
Accrued expenses			919				973
Payroll liabilities			1,862				1,654
Other current liabilities			1,507				1,803
Total current liabilities			4,967				5,236
Total liabilities			4,967				5,236
Commitments and contingencies			—				—
Stockholders’ equity
Convertible preferred stock – $0.001 par value; 10,000,000 shares authorized; 582 shares issued and outstanding as of December 31, 2024 and 2023			—				—
Common stock – $0.18 par value; 350,000,000 and 175,000,000 shares authorized as of December 31, 2024 and 2023, respectively; 129,170,004 and 125,304,064 shares issued and outstanding as of December 31, 2024 and 2023, respectively			23,488				22,792
Additional paid-in capital			261,256				255,987
Treasury stock, at cost; 1,320,046 shares of common stock at December 31, 2024 and 2023			(1,475	)			(1,475	)
Accumulated deficit			(211,792	)			(186,288	)
Total stockholders’ equity			71,477				91,016
Total liabilities and stockholders’ equity		$	76,444			$	96,252

ATOSSA THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(amounts in thousands, except share and per share data)
		For the Year Ended December 31,
		2024				2023
Operating expenses
Research and development		$	14,117			$	17,334
General and administrative			13,504				14,043
Total operating expenses			27,621				31,377
Operating loss			(27,621	)			(31,377	)
Impairment charge on investment in equity securities			(1,710	)			(2,990	)
Interest income			4,050				4,343
Other expense, net			(223	)			(70	)
Loss before income taxes			(25,504	)			(30,094	)
Income tax benefit			—				—
Net loss			(25,504	)			(30,094	)
Net loss per share of common stock – basic and diluted		$	(0.20	)		$	(0.24	)
Weighted average shares outstanding used to compute net loss per share – basic and diluted			125,859,276				126,081,602

TORONTO, March 25, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will host a hybrid (in-person and virtual) investor event on Monday, April 28, 2025, during the American Urological Association’s (“AUA”) Annual Meeting in Las Vegas, NV, from 3:30 p.m. to 5:00 p.m. Pacific Time (6:30 p.m. to 8:00 p.m. Eastern Time).

“The program will feature presentations from members of Profound’s management team as well as by leading physicians on: (1) TULSA-PRO^® and its unrivalled flexibility to treat a wide variety of prostate disease patients; (2) peri-operative results from the Level 1 CAPTAIN post-market study comparing the TULSA procedure to radical prostatectomy in men with localized prostate cancer; (3) the upcoming TULSA-AI^® module for BPH, including a live demonstration of the technology; and (4), the progress we are making with our TULSA+ program, which combines the TULSA-PRO^® system and consumables with Siemens Healthineers’ interventional MRI, Magnetom Free.Max, as a total prostate solution,” commented Arun Menawat, Profound’s CEO and Chairman.

About Profound Medical Corp.

Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue.

Profound is commercializing TULSA-PRO^®, a technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO^® system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. TULSA employs real-time MR guidance for precision to preserve patients’ urinary continence and sexual function, while killing the targeted prostate tissue via precise sound absorption technology that gently heats it to 55-57°C. TULSA is an incision- and radiation-free “one-and-done” procedure performed in a single session that takes a few hours. Virtually all prostate shapes and sizes can be safely, effectively, and efficiently treated with TULSA. There is no bleeding associated with the procedure; no hospital stay is required; and most TULSA patients report quick recovery to their normal routine. TULSA-PRO^® is CE marked, Health Canada approved, and 510(k) cleared by the U.S. Food and Drug Administration (“FDA”).

Profound is also commercializing Sonalleve^®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve^® has also been approved by the China National Medical Products Administration for the non-invasive treatment of uterine fibroids and has FDA approval under a Humanitarian Device Exemption for the treatment of osteoid osteoma. Profound is in the early stages of exploring additional potential treatment markets for Sonalleve^® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.

Forward-Looking Statements

This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, BPH, uterine fibroids, palliative pain treatment and osteoid osteoma; and the success of Profound’s U.S. commercialization strategy and activities for TULSA-PRO^®. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “is expected”, “expects”, “scheduled”, “intends”, “contemplates”, “anticipates”, “believes”, “proposes” or variations (including negative variations) of such words and phrases, or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks regarding the medical device industry, regulatory approvals, reimbursement, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Other factors and risks that may cause actual results to differ materially from those set out in the forward-looking statements are described in Profound’s Annual Report on Form 10-K and other filings made with U.S. and Canadian securities regulators, available at www.sedarplus.ca and www.sec.gov. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.

For further information, please contact:

Stephen Kilmer
Investor Relations
[email protected]
T: 647.872.4849

AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) — BigCommerce (Nasdaq: BIGC), a leading provider of open, composable commerce solutions for B2C and B2B brands and retailers, today unveiled innovative enhancements to its B2B products designed to help sales teams operate more efficiently and streamline processes so they can respond quickly to market demands and focus on growth.

These updates, Configure-Price-Quote (CPQ) and Multi-Company Account Hierarchy and Advanced Permissioning, enable faster quote conversion and minimize redundant account management processes so that merchants can respond dynamically to market demands and scale without being bogged down by manual tasks.

“For manufacturers, distributors and wholesalers, improving efficiency is the name of the game,” said Lance Owide, general manager of B2B at BigCommerce. “The updates BigCommerce is announcing today mark a huge step forward to help organizations streamline their operations and allow sales teams to focus on customer relationships instead of managing workflows.”

“BigCommerce continues to lead the way in B2B ecommerce, and these latest enhancements are a gamechanger,” said Amandeep Singh, founder and president of BigCommerce partner Cronix. “We’re especially excited about the Multi-Company Account Hierarchy—an invaluable addition for enterprise merchants needing better access control, management and reporting for companies with multiple branches. Along with the new control panel, enhanced quoting engine and API improvements, these features bring more power and flexibility to B2B sellers. We’re excited about where BigCommerce is headed and the impact these innovations will have on merchants.”

The new Enhanced Account Hierarchy and Advanced Permissioning includes:

• Support for multi-tier account structures
• Intuitive configuration tools for quick replication of complex buyer organizational setups
• Granular, role-based access and dynamic permissioning for secure account management
• Simplified bulk invoice payments and aggregated account data views
• Self-service features for buyers to view invoices, orders and financial data across accounts
• Streamlined assignments and delegated control to reduce manual administrative tasks

Designed for today’s complex B2B environment, these enhancements support enterprise-level account hierarchies and detailed, role-based permissions, unlocking the ability to scale rapidly while maintaining a personalized, high-touch customer experience. These features benefit B2B merchants by providing a platform that not only adapts to organizational structures but also accelerates sales cycles and enhances customer loyalty whether they’re selling to franchises or multinational corporations. The system’s advanced permissioning and intuitive account hierarchy enable faster negotiations, quicker decision-making and long-term scalability, ensuring a superior competitive edge in a fast-moving market.

“We can begin to truly extend our business towards that B2B2C vision model,” said Donald P. Polansky, senior manager of corporate systems development at GlassCraft Door Company, one of BigCommerce’s B2B customers. “Whether our direct customer has 2 or 20 locations, we can tailor their accounts to match their corporate structures and even bring their client’s business customers into our ecosystem. Working together with BigCommerce and their B2B team gives us a continual disruptive advantage without destroying the business foundations that already exist.”

“BigCommerce’s Multi-Company Hierarchy feature allows us to more easily support merchants whose buyers manage payment and credit limits at the HQ level, within a single screen,” said Matt Sandham, director at Bspoq, a BigCommerce agency partner. “We’re also able to put multiple companies who belong in the same group into a singular reference number for a more seamless integration with the buyer’s ERP. Our merchants’ account management teams say it has made huge time savings and significantly reduced the admin involved in setting up and managing their customer accounts.”

CPQ was built to help B2B businesses accelerate quote-to-cash cycles, drive revenue growth and improve customer satisfaction. With a streamlined quoting process, sales teams can spend more time building relationships and closing deals.

The new CPQ product features:

• Single-page, mobile-optimized quote interface
• Configurable quote views with customizable fields
• Built-in company account creation and quick add products
• Integrated shipping & tax API for real-time calculations
• Auto-quoting options and tailored discount view controls
• Support for both B2B and B2C quoting channels

“CPQ will help our clients speed up their quote approval processes,” Adam Thibodeaux, senior vice president of global sales at McFadyen Digital. “It will streamline call-in orders for our clients who take orders by phone, helping their sales teams and customers transition to self-service.”

“These innovations represent a forward-thinking approach to B2B ecommerce by marrying agility with enterprise-grade functionality without enterprise-level costs,” Owide said. “They reflect BigCommerce’s commitment to evolving its platform to meet increasingly complex use cases without added costs, technical debt and administrative overhead, positioning the company not only as a robust ecommerce solution provider but as a strategic partner in digital transformation.”

To learn more about BigCommerce’s B2B ecommerce solutions, click here.

About BigCommerce

BigCommerce (Nasdaq: BIGC) is a leading open SaaS and composable ecommerce platform that empowers brands, retailers, manufacturers and distributors of all sizes to build, innovate and grow their businesses online. BigCommerce provides its customers sophisticated professional-grade functionality, customization and performance with simplicity and ease-of-use. Tens of thousands of B2C and B2B companies across 150 countries and numerous industries rely on BigCommerce, including Coldwater Creek, Harvey Nichols, King Arthur Baking Co., MKM Building Supplies, United Aqua Group and Uplift Desk. For more information, please visit www.bigcommerce.com or follow us on X and LinkedIn.

BigCommerce® is a registered trademark of BigCommerce Pty. Ltd. Third-party trademarks and service marks are the property of their respective owners.

Media Contact:

Brad Hem
[email protected]

WESTLAKE VILLAGE, Calif., March 25, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (to be listed on the NASDAQ Global Market under the symbol NTHI), a clinical-stage medical biotechnology company, announced today that Dr. Victoria Medvec, has been appointed to its Board of Directors. Dr. Medvec is the Chief Executive Officer of Medvec and Associates, a valued adviser to executives and boards at a substantial portion of Fortune 100 companies.

“We are thrilled to leverage Victoria’s extensive experience in strategic partnerships, global market access, and regulatory negotiations,” said Dr. Thomas Chen, Chief Executive Officer of NeOnc. “She brings invaluable expertise on high-stakes issues including mergers and acquisitions, customer contracts, and supplier agreements, among others. Over her illustrious career, Victoria has advised prominent life sciences clients such as Amgen, AstraZeneca, Bristol Myers Squibb, Gilead, Pfizer, and Sanofi. Her presence on our Board enhances our potential for success, and will be invaluable as we work toward the successful commercialization of central nervous system therapeutics.”

With a wealth of experience as a public and private board director, Dr. Medvec employs her expertise in negotiations and decision making to help companies drive revenue growth through optimization, risk management, corporate governance and mergers and acquisitions. Her research has been published in esteemed academic journals including Psychological Review and the Journal of Personality and Social Psychology. Additionally, she is the author of the best-selling book “Negotiate Without Fear.”

“I am honored to join NeOnc’s Board of Directors at such an exciting time,” said Dr. Medvec. “I am passionate about the Company’s commitment to advancing innovative therapies for patients in need, and I look forward to working alongside a talented team to support NeOnc in achieving its mission to bring transformative solutions to patients living with debilitating brain tumors.”

“Dr. Medvec’s strategic value to our company is significant,” said Amir Heshmatpour, NeOnc’s Executive Chairman. “We anticipate receiving significant benefits from her insights and guidance as NeOnc advances its infrastructure and clinical trials, while exploring potential partnerships within the biotech industry.”

Dr. Medvec holds the Adeline Barry Davee Professorship of Management and Organizations at Northwestern University’s Kellogg School of Management, where she has been a distinguished faculty member since 1995. She is the co-founder of the Kellogg Center for Executive Women. Her research has garnered attention from prestigious publications such as the Wall Street Journal, the New York Times, the Washington Post, and the Today Show.

Dr. Medvec earned her Bachelor of Arts degree from Bucknell University and obtained her Ph.D. in Psychology from Cornell University.

ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.

NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood-brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast-Track and Investigational New Drug (IND) status.
The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.

For more about NeOnc and its pioneering technology, visit neonctech.com.

Important Cautions Regarding Forward Looking Statements

All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Generally, such forward-looking statements include statements regarding expectations, possible or assumed future actions, business strategies, events or results of operations, including statements regarding our expectations or predictions or future financial or business performance or conditions and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate,” or similar expressions. The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions. Actual results could differ materially from current projections or implied results. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management are under no obligation, and expressly disclaim any obligation, to update, alter or otherwise revise any forward-looking statements following the date of this news release, whether because of new information, future events or otherwise, except as required by law.

“NEO100” is a registered trademark of NeOnc Technologies Holdings, Inc.

Company Contact:

Patrick Walters
Chief Operations Officer
NeOnc Technologies Holdings, Inc.
[email protected]

Investor Relations:     

Roger Pondel / Laurie Berman
PondelWilkinson Inc.
(310) 279-5980
[email protected]
[email protected]

KANSAS CITY, Mo., March 25, 2025 (GLOBE NEWSWIRE) — H&R Block, Inc. (NYSE: HRB), a leading provider of global tax preparation, financial products and small business solutions, today announced that Phillip Miller will join the company as the new Vice President and Chief Information Security Officer (CISO) as of March 31.

“We are thrilled to welcome Phillip to our leadership team,” said Dara Redler, Chief Legal and Administrative Officer. “His extensive experience and innovative approach to information security will be invaluable as we continue to prioritize protecting our clients.”

Miller brings over 15 years of executive security experience across retail, manufacturing, and technology sectors. Miller has built and maintained strategic programs for companies to meet security, legal, privacy and regulatory frameworks.

Most recently, Phillip founded Qurple, LLC, where he served as an advisor and consultant for numerous companies. Prior to that, he held Vice President/Chief Information Security Officer roles at NetApp and Brooks Brother. Miller has also served as a Principal Security Advisor at Amazon Web Services where he advised financial services, health services, financial technology, and investment management companies on secure cloud computing and compliance strategies.

Miller is the author of “Hacking Success,” a book on information security policy and artificial intelligence. He holds a UK law degree, is a Certified Information Systems Security Professional (CISSP), and actively participates in privacy, ethics, and technology law forums.

About H&R Block

H&R Block, Inc. (NYSE: HRB) provides help and inspires confidence in its clients and communities everywhere through global tax preparation services, financial products, and small-business solutions. The company blends digital innovation with human expertise and care as it helps people get the best outcome at tax time and also be better with money using its mobile banking app, Spruce. Through Block Advisors and Wave, the company helps small-business owners thrive with year-round bookkeeping, payroll, advisory, and payment processing solutions. For more information, visit H&R Block News.

Media Contacts:
Media Relations:	Lexi Ryan, (816) 877-7076, [email protected]
	Media Desk, [email protected]
Investor Relations:	Jordyn Eskijian, (816) 854-5674, [email protected]

NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) — Xcel Brands (NASDAQ: XELB), an industry leading media and consumer products company specializing in building influencer-driven brands through social commerce and livestreaming, is proud to announce an exciting partnership with internationally renowned baker and chef, best-selling author, and creator of Bigger Bolder Baking, Gemma Stafford. Together, they will launch an innovative bakeware, food, and home brand designed to bring professional-quality tools and delicious foods to home bakers and entertainers everywhere—without sacrificing design quality or affordability.

This launch marks Gemma Stafford’s first-ever venture into developing her own product line, a milestone moment for her brand and community. For the first time, Gemma is bringing her expertise beyond the screen and into homes worldwide, carefully curating a line of bakeware, cookware, kitchen tools, and home essentials that embody her joyful and approachable philosophy. To ensure the highest quality and thoughtful design, she has chosen to partner with Xcel Brands. Together, they are creating a collection that blends functionality with timeless style, inspired by Gemma’s Irish heritage, vintage charm, and bold creativity. From beautifully crafted tools to simple yet delicious food products, this collection makes baking, cooking, and entertaining at home more elevated, effortless, and accessible than ever before.

“Over the past 11 years, I’ve reached millions of home bakers, learning firsthand what excites them, what challenges them, and what they truly need in their kitchens to be bold, confident bakers. Partnering with Xcel Brands allows me to create products that are practical, delightful, and designed to spark creativity for bakers everywhere—drawing from my professional expertise and years of hands-on experience to make them indispensable in any home kitchen.”

Xcel Brands, known for its expertise in building powerful lifestyle brands, sees this partnership as a natural fit. With millions of devoted fans across YouTube, social media, and BiggerBolderBaking.com, Gemma has built a global community of passionate home bakers. Her engaging content inspires both beginners and seasoned bakers to create with confidence.

“We are thrilled to partner with Gemma Stafford to launch this brand. Her expertise and deep love of baking and her influence align perfectly with Xcel’s vision of creating innovative, lifestyle-driven consumer brands,” stated Robert W. D’Loren, Chairman and Chief Executive Officer of Xcel Brands. “This collaboration brings us one step closer to our goal of reaching over 100 million social media followers across our brand portfolio, reinforcing our commitment to transforming how consumers engage with the brands they love.”

The home baking and entertaining market offers strong potential for a brand focused on quality, accessibility, and expertise. This partnership will provide high-quality products and educational resources for all bakers. By combining practical design with Gemma Stafford’s style, the brand aims to establish itself in the growing culinary market, addressing the needs of home cooks and entertainers. The brand is set to launch in Spring 2026 with availability through select retailers, e-commerce platforms, and live shopping channels. Stay updated on this exciting journey at www.xcelbrands.com  

About Xcel Brands
Xcel Brands, Inc. (NASDAQ: XELB) is a media and consumer products company engaged in the design, licensing, marketing, live streaming, and social commerce sales of branded apparel, footwear, accessories, fine jewelry, home goods and other consumer products, and the acquisition of dynamic consumer lifestyle brands. Xcel was founded in 2011 with a vision to reimagine shopping, entertainment, and social media as social commerce. Xcel owns the Halston, Judith Ripka, and C. Wonder brands, as well as the Tower Hill by Christie Brinkley co-branded collaboration, and holds noncontrolling interests in the Isaac Mizrahi brand and Orme Live. Xcel also owns and manages the Longaberger brand through its controlling interest in Longaberger Licensing LLC. Xcel has recently announced the launch of new pet brand, Trust-Respect-Love by Cesar Millan. Xcel is pioneering a true modern consumer products sales strategy which includes the promotion and sale of products under its brands through interactive television, digital live-stream shopping, social commerce, brick-and-mortar retail, and e-commerce channels to be everywhere its customers shop. The company’s brands have generated in excess of $5 billion in retail sales via livestreaming in interactive television and digital channels alone, growing social media presence of 35+ million followers across their brand profile and talent, and over 20,000 hours of livestream content production time and social commerce. Headquartered in New York City, Xcel Brands is led by an executive team with significant live streaming, production, merchandising, design, marketing, retailing, and licensing experience, and a proven track record of success in elevating branded consumer products companies. www.xcelbrands.com

About Gemma Stafford

For more than a decade, Irish-born chef Gemma Stafford has been bringing her passion for teaching people how to bake with confidence to her top online baking show and brand, Bigger Bolder Baking. Today, with more than 8 million followers (“Bold Bakers”) and half a billion video views to date, Bigger Bolder Baking has become the leading – and indispensable – multimedia destination for bakers. Gemma’s unique combination of expertise, bold recipes, and approachable techniques have led to appearances as a judge on Netflix’s Nailed It!, Food Network’s Best Baker in America, and Hulu’s Baker’s Dozen, along with appearances on national and local TV nationwide. Gemma is also the co-creator and host of the #1 baking entertainment podcast, Knead To Know, which releases every week in partnership with HRN. In 2025, she will launch the first-ever baking TV network, the Bold Baking Network, on connected television (CTV) and free ad-supported streaming television (FAST) platforms dedicated to educating and entertaining home bakers 24/7.

For further information please contact:

Seth Burroughs
Xcel Brands
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/adc0138c-10f6-455e-af91-c407f610a729

Shenzhen, China, March 25, 2025 (GLOBE NEWSWIRE) — ZJK Industrial Co. Ltd. (NASDAQ: ZJK) (“ZJK Industrial”, “ZJK” or the “Company”), a high-tech precision parts and hardware manufacturer for artificial intelligence (AI) infrastructure, consumer electronics, electric vehicles, aerospace and other smart technologies, today announced that the Company is scaling operations to meet increasing demand for its products across key verticals. 

In response to the rising demand and to fulfil a growing pipeline of purchase orders, ZJK has expanded its production lines, upgraded facility capabilities, increased capacity at several machining centers and added new equipment, including high-precision Computer Numerical Control (CNC) lathes, milling machines, and multi-station cold-forging machines.

More updates, including finalized purchase orders and production timelines, are expected to be announced in the coming weeks.

“We continue to expand our operations in response to growing demand for our products,” said ZJK CEO, Ning Ding. “We remain committed to delivering reliability, scale, and speed, especially as the need for trusted global suppliers continues to rise.” 

About ZJK Industrial Co., Ltd.

ZJK Industrial Co., Ltd. is a high-tech enterprise specializing in the manufacturing and sale of precision fasteners, structural parts and other precision metal parts applied in a variety of industries, including intelligent electronic equipment, new energy vehicles, aerospace, energy storage systems, medical and liquid cooling systems used in artificial intelligence supercomputers. With over fourteen years in the precision metal parts manufacturing industry, the Company maintains a skilled professional team, a series of highly automated and precision manufacturing equipment, stable and strong customer group, and complete quality management systems. ZJK mainly offers standard screws, precision screws and nuts, high-strength bolts and nuts, turning parts, stamping parts and CNC machining parts, CNC milling parts, high precision structural components, Surface Mounting Technology (SMT) for miniature parts packaging, and technology service for research and development from a professional engineering team. For more information, please visit the Company’s website at https://ir.zjk-industrial.com/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “likely to” or other similar expressions in this announcement. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the U.S. Securities and Exchange Commission.

For more information, please contact:

ZJK Industrial Co., Ltd.
Phone: +86-755-28341175
Email: [email protected]

Daniel Kennedy – U.S. Director of Business Development
Phone: +1 (646) 256-3453
Email: [email protected]

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: [email protected]

TAMPA, Fla., March 25, 2025 (GLOBE NEWSWIRE) — LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin mining and technology-based specialty finance company, today announced that it has scheduled its fourth quarter and full year 2024 earnings conference call and webcast for Monday, March 31, 2025 at 8:00 AM EST.

LM Funding will publish its fourth quarter and full year 2024 results as well as an accompanying investor presentation the morning of March 31, 2025 before the call. A copy of the earnings release and investor presentation will be available on the Company’s Investor Relations website at https://www.lmfunding.com/investors.

Conference Call Details:

• Date: March 31, 2025
• Time: 8:00 AM EST
• Participant Call Links:
  • Live Webcast: Link
  • Participant Call Registration: Link

About LM Funding America

LM Funding America, Inc. (Nasdaq: LMFA), operates as a Bitcoin mining and specialty finance company. The company was founded in 2008 and is based in Tampa, Florida. For more information, please visit https://www.lmfunding.com.

For investor and media inquiries, please contact: 

Investor Relations 
Orange Group 
Yujia Zhai 
[email protected]

CULVER CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) — Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or “the Company”), a leading, global independent developer and publisher of interactive digital entertainment, announced today that it will report financial results for the fourth quarter and full year ended December 31, 2024 on Wednesday, March 26, 2025. Management will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss the results.

Participants may listen to the live webcast and replay on the Company’s investor relations website at https://investor.snail.com/.

About Snail, Inc.

Snail is a leading, global independent developer and publisher of interactive digital entertainment for consumers around the world, with a premier portfolio of premium games designed for use on a variety of platforms, including consoles, PCs and mobile devices.

Contacts:

Investors:
[email protected]

Press:
[email protected]

NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, announces that its chief medical officer, Roger Waltzman, M.D., M.B.A. will be moderating a panel at the annual CMO360 Summit, being held April 7-8 in Boston.

Dr. Waltzman’s panel, titled “Ensuring Effective and Efficient Trials Through Clinical Operations” will be Monday, April 7^th from 4:05PM – 4:35PM ET.

Jeffrey Meckler, Indaptus CEO, commented, “These opportunities serve as continued validation for our approach to clinical trial management, reinforcing its potential to enhance efficiency, an essential factor in our industry. We appreciate this esteemed conference’s recognition and look forward to Roger’s panel, anticipating valuable insights from the discussion.”

The CMO Summit 360° ®, operated by The Conference Forum, is the largest gathering of biotech Chief Medical Officers across indications, modalities, company stages, professional experience levels and geographic locations. This is the conference to connect with peers and develop the skills needed to succeed as a biotech CMO. The Conference Forum is a life science industry research, conference development and marketing firm. The company brings the full spectrum of executives together to share ideas and information on how to advance efficient medicine development and delivery, patient diversity and access. 

About Indaptus Therapeutics

Indaptus Therapeutics has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The product candidates are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy product candidates represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas, pancreatic and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts. In pre-clinical studies tumor eradication was observed with Decoy product candidates in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models produced innate and adaptive immunological memory, involved activation of both innate and adaptive immune cells, and was associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product candidate, with associated “cold” to “hot” tumor inflammation signature transition. IND-enabling, nonclinical toxicology studies demonstrated i.v. administration without sustained induction of hallmark biomarkers of cytokine release syndromes, possibly due to passive targeting to liver, spleen, and tumor, followed by rapid elimination of the product candidate. Indaptus’ Decoy product candidates have also produced meaningful single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

For more information, visit www.indaptusrx.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act. These include statements regarding management’s expectations, beliefs and intentions regarding, among other things, our expectations and plans regarding our Phase 1 clinical trial of Decoy20 and the anticipated effects of our product candidates, including Decoy20. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to the following: our limited operating history; conditions and events that raise substantial doubt regarding our ability to continue as going concern; the need for, and our ability to raise, additional capital given our lack of current cash flow; our clinical and preclinical development, which involves a lengthy and expensive process with an uncertain outcome; our incurrence of significant research and development expenses and other operating expenses, which may make it difficult for us to attain profitability; our pursuit of a limited number of research programs, product candidates and specific indications and failure to capitalize on product candidates or indications that may be more profitable or have a greater likelihood of success; our ability to obtain and maintain regulatory approval of any product candidate; the market acceptance of our product candidates; our reliance on third parties to conduct our preclinical studies and clinical trials and perform other tasks; our reliance on third parties for the manufacture of our product candidates during clinical development; our ability to successfully commercialize Decoy20 or any future product candidates; our ability to obtain or maintain coverage and adequate reimbursement for our products; the impact of legislation and healthcare reform measures on our ability to obtain marketing approval for and commercialize Decoy20 and any future product candidates; product candidates of our competitors that may be approved faster, marketed more effectively, and better tolerated than our product candidates; our ability to adequately protect our proprietary or licensed technology in the marketplace; the impact of, and costs of complying with healthcare laws and regulations, and our failure to comply with such laws and regulations; information technology system failures, cyberattacks or deficiencies in our cybersecurity; and unfavorable global economic conditions. These and other important factors discussed under the caption “Risk Factors” included in our most recent Annual Report on Form 10-K filed with the SEC on March 13, 2025, and our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release. We undertake no obligation to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events, except as required by applicable law.

Contact: 
[email protected]

Investor Relations Contact:

CORE IR
Louie Toma
[email protected]